Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3525 plus Osimertinib in Advanced NSCLC
NCT05284994Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQ-B3525 in non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
TQ-B3525
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05284994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284994.